Diabetic Gastroparesis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Diabetic Gastroparesis – Pipeline Review, H2 2017’, provides an overview of the Diabetic Gastroparesis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis

The report reviews pipeline therapeutics for Diabetic Gastroparesis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Diabetic Gastroparesis therapeutics and enlists all their major and minor projects

The report assesses Diabetic Gastroparesis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Cempra Inc

Evoke Pharma Inc

GlaxoSmithKline Plc

Johnson & Johnson

Theravance Biopharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Diabetic Gastroparesis - Overview

Diabetic Gastroparesis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Diabetic Gastroparesis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Gastroparesis - Companies Involved in Therapeutics Development

Allergan Plc

Cempra Inc

Evoke Pharma Inc

GlaxoSmithKline Plc

Johnson & Johnson

Theravance Biopharma Inc

Diabetic Gastroparesis - Drug Profiles

camicinal - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CEM-031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETX-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETX-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metoclopramide hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prucalopride succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relamorelin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

renzapride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

velusetrag hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Diabetic Gastroparesis - Dormant Projects

Diabetic Gastroparesis - Discontinued Products

Diabetic Gastroparesis - Product Development Milestones

Featured News & Press Releases

Aug 09, 2017: EndoLogic Announces Feedback from Positive FDA Meeting for Renzapride in Diabetic Gastroparesis

May 31, 2017: Evoke Pharma Enters Agreement with Rho to Submit NDA for Gimoti

May 15, 2017: Evoke Pharma Provides Update on Gimoti

May 10, 2017: Evoke Pharma Presents Gimoti Efficacy and Safety Data from Phase 3 Trial as Late Breaker at Digestive Disease Week 2017

May 03, 2017: EndoLogic Announces Scheduling of pre-IND Meeting with FDA to Discuss Renzapride in Diabetic Gastroparesis

May 01, 2017: Allergan to Present Data on Relamorelin at Digestive Disease Week 2017

Apr 04, 2017: Positive Type A Meeting with FDA Confirms Acceptability of Evoke Pharma's Proposed Comparative Exposure PK Trial for Gimoti NDA

Mar 21, 2017: Evoke Pharmas Phase 3 Results for Gimoti Accepted as Late-Breaker for Presentation at Digestive Disease Week 2017

Jan 04, 2017: Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial

Dec 15, 2016: Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti

Dec 06, 2016: Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis

Sep 07, 2016: Evoke Pharma Announces Positive Non-Clinical Pre-NDA Meeting with FDA for Gimoti

Jul 26, 2016: Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001

Jul 18, 2016: Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial

Jul 07, 2016: Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Diabetic Gastroparesis, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Diabetic Gastroparesis – Pipeline by Allergan Plc, H2 2017

Diabetic Gastroparesis – Pipeline by Cempra Inc, H2 2017

Diabetic Gastroparesis – Pipeline by Evoke Pharma Inc, H2 2017

Diabetic Gastroparesis – Pipeline by GlaxoSmithKline Plc, H2 2017

Diabetic Gastroparesis – Pipeline by Johnson & Johnson, H2 2017

Diabetic Gastroparesis – Pipeline by Theravance Biopharma Inc, H2 2017

Diabetic Gastroparesis – Dormant Projects, H2 2017

Diabetic Gastroparesis – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Diabetic Gastroparesis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports